Context Therapeutics (CNTX) Insider Pasternak Buys 45,000 Shares
Insider Andy Pasternak purchased 45,000 shares of Context Therapeutics on June 24, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Andy Pasternak bought 45,000 shares of Context Therapeutics Inc. ($CNTX) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CNTX is up 5.2% after 1 week, up 5.2% after 1 month and down 58.6% to date (from the $0.58 close on Jun 24, 2026).
CNTX
Context Therapeutics Inc.
Key Points
- Andy Pasternak bought 45,000 shares of Context Therapeutics Inc. (CNTX) on June 24, 2026, at a price of $0.58 per share.
- This purchase fits a pattern of recent insider buying, as four other insiders also acquired 45,000 shares each on the same date.
- Context Therapeutics has a market cap of about $34.5 million and is currently trading near its 52-week low of $0.34.
Get $CNTX trade alerts by text
We text you when insiders, Congress or big funds trade $CNTX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Context Therapeutics Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Context Therapeutics Inc.
Andy Pasternak acquired 45,000 shares of Context Therapeutics Inc. (CNTX) on June 24, 2026. This purchase comes at a price of $0.58 per share, reflecting a total investment of about $26,100. This move follows similar transactions by other insiders on the same day.
Other Insiders Join the Buying Trend
On June 24, 2026, several other insiders also bought shares of Context Therapeutics. Walker Luke Nathaniel, Linda West, Stacey Jennifer Evans, and Karen Smith each purchased 45,000 shares. Each of these transactions further strengthens their stakes in the company, indicating a collective confidence among the insiders.
Stock Performance Near 52-Week Low
Context Therapeutics is currently trading at around $0.58, which is close to its 52-week low of $0.34. The stock has fluctuated between $0.34 and $3.62 over the past year. This recent buying activity by insiders may suggest they believe the stock is undervalued at its current price.
What Context Therapeutics Inc. Does
Context Therapeutics is a clinical-stage biopharmaceutical company based in Philadelphia, PA, focused on developing treatments for solid tumors. Their lead product candidate, CTIM-76, targets cancer cells expressing CLDN6, reflecting the company's commitment to innovative cancer therapies.
What’s Next for Context Therapeutics
The next earnings report for Context Therapeutics is scheduled for May 7, 2025. As a reminder, the recent insider trades reflect positions as of June 24, 2026, and may not represent current holdings. Investors will be watching for any further developments or filings that could affect the company's trajectory.
Related Filing Alerts
Source: Andy Pasternak's Form 4 filing on $CNTX (Jun 24, 2026). Find the original filing: CNTX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts